Liver function and drug processing: a new study

NCT ID NCT04271488

Recruiting now Knowledge-focused Sponsor: Eisai Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 12, 2026 · Last updated May 13, 2026 · Updated 25 times

Summary

This study looks at how mild or moderate liver problems change the way the body handles a single dose of the drug tasurgratinib. Researchers will compare 18 adults with stable liver impairment to healthy volunteers. The goal is to understand how the liver affects drug levels in the blood, which helps guide safe dosing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Eisai Trial Site #1
RECRUITING

Mintato-ku, Tokyo, Japan
Eisai Trial Site #2
RECRUITING

Yuhu, Oita Prefecture, Japan
Eisai Trial Site #3
RECRUITING

Bukyo-ku, Tokyo, Japan
Eisai Trial Site #4
TERMINATED

Kurume, Fukuoka, Japan
Eisai Trial Site #5
RECRUITING

Kofu, Yamanashi, Japan
Eisai Trial Site #6
RECRUITING

Hakata, Fukuoka, Japan
Eisai Trial Site #7
RECRUITING

Kyoto, Japan
Eisai Trial Site #8
RECRUITING

Shinjuku-ku, Tokyo, Japan

Conditions

Explore the condition pages connected to this study.

HEPATIC IMPAIRMENT